Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
2017-004295-55Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Primary endpoint: Long-term safety of ozanimod. Started Jan 2018; status: active.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-004295-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004295-55.